Davis Polk advised the joint book-running managers in the deal.
NeoGenomics, Inc. executed its $345 million aggregate principal amount of its 0.250% convertible senior notes due 2028, which included $45 million aggregate principal amount of notes issued pursuant to the exercise in full of the underwriters’ option to purchase additional notes. In addition, Davis Polk advised counterparties to capped call transactions in connection with the convertible senior notes offering.
BofA Securities, Inc., Morgan Stanley & Co. LLC, Goldman Sachs & Co. LLC, SVB Leerink LLC, Craig-Hallum Capital Group LLC, Needham & Company, LLC, Raymond James & Associates, Inc., and Stephens Inc. acted as joint book-running managers for the offerings.
In addition, NeoGenomics executed a concurrent $230 million SEC-registered offering of 4,693,876 shares of its common stock, which included 612,244 shares from the full exercise of the underwriters’ option to purchase additional shares.
Headquartered in Fort Myers, Florida, NeoGenomics operates a network of cancer-focused testing laboratories in the United States as well as in Switzerland and Singapore.
The Davis Polk corporate team included partner Alan F. Denenberg (Picture), counsel Jason Bassetti and associate Claire A. Bacon. The equity derivatives team included partner Mark M. Mendez and associates Annie Li and Danielle Forni. The tax team included partner Michael Farber and associate Yixuan Long. Partner Frank J. Azzopardi and associate Christopher C. Woller provided intellectual property advice.
Involved fees earner: Frank Azzopardi – Davis Polk & Wardwell; Claire Bacon – Davis Polk & Wardwell; Jason Bassetti – Davis Polk & Wardwell; Alan Denenberg – Davis Polk & Wardwell; Michael Farber – Davis Polk & Wardwell; Danielle Forni – Davis Polk & Wardwell; Annie Li – Davis Polk & Wardwell; Yixuan Long – Davis Polk & Wardwell; Mark Mendez – Davis Polk & Wardwell; Christopher Woller – Davis Polk & Wardwell;
Law Firms: Davis Polk & Wardwell;